BioNano Genomics Inc vs Mondaycom Ltd — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Mondaycom Ltd trades at $85.48 (market cap $3.70B). The key difference: Mondaycom Ltd is far larger — about 270.9× BioNano Genomics Inc's market cap, and Mondaycom Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MNDY | |
|---|---|---|
Market Cap | $13.66M | $3.70B |
Sector | Health | Technology |
52-Week High | $4.92 | $219.15 |
52-Week Low | $1.06 | $58.81 |
Enterprise Value | $16.26M | $2.86B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Monday.com (MNDY) trades at $85.95, down 3.01% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $1.48 versus $1.11 expected, and revenue growth of 22% year-over-year. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target.
Outlook is cautiously optimistic due to robust earnings beats and AI product growth, but near-term risks include slower revenue guidance and competitive pressures. The high P/E of 37.04 suggests premium valuation, demanding sustained execution. Investors should weigh strong profitability against guidance concerns for balanced exposure.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →